Posted by Michael Wonder on 02 Feb 2026
MoonLake announces FDA fast track designation for sonelokimab palmoplantar pustulosis
2 February 2026 - MoonLake Immunotherapeutics today announces that the FDA has granted fast track designation for sonelokimab for the treatment of moderate to severe palmoplantar pustulosis.
MoonLake had submitted a request for fast track designation on 1 December 2025.
